| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.4 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.4 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |